Last updated: February 21, 2026
Ursodiol (uric acid derivative) is a marketed drug primarily used for dissolving certain types of gallstones and treating primary biliary cirrhosis. As a pharmaceutical asset, it offers a stable revenue stream due to its established safety profile and extensive patent protections, with opportunities for extension through formulations or new indications.
Market Overview
Ursodiol’s core indications include gallstone dissolution and primary biliary cirrhosis (PBC). It is marketed under brand names such as Actigall (AbbVie/Forest). The global market revenue was approximately $600 million in 2022, with North America accounting for 60% of sales and Europe at 25%. The drug’s existing patent protection lasts until 2024-2025, after which generic competition is projected to erode revenue margins.
Key Market Drivers
- Increasing prevalence of gallstone disease: Approximately 10-15% of adults in developed nations have gallstones (Sjövall et al., 2017).
- Rising PBC cases: Estimated at around 200,000 cases globally, with higher diagnosis rates due to improved detection techniques (Lau et al., 2018).
- Growing elderly population: Age is a significant risk factor for gallstones and PBC.
Competitive Landscape
| Drug |
Manufacturer |
Year Approved |
Patent Status |
Annual Sales |
Main Indications |
| Ursodiol |
Various (Generic late 2020s) |
1978 |
Patent expired, generic off-patent |
$600M (2022) |
Gallstones, PBC |
| Obeticholic Acid |
Intercept Pharmaceuticals |
2016 |
Patent until 2035 |
$200M (2022) |
PBC, NASH alternative |
| Fenofibrate |
Several |
1960s |
Off-patent |
$1.2B (annual, broader lipid indication) |
Lipid disorders |
The entry of generics after patent expiration is expected to reduce Ursodiol’s profitability unless branded formulations or new indications are developed.
Investment Considerations
Revenue Stability
Ursodiol’s long history and broad indication profile establish a predictable revenue stream, especially in developed markets where off-label use is regulated.
Patent and Regulatory Risks
Patent expiry in mid-2020s presents a risk of generic price erosion. Companies could mitigate this through:
- Diversification into new formulations (e.g., extended-release versions).
- Clinical research for new indications (e.g., non-alcoholic fatty liver disease).
Development Opportunities
Research into ursodiol derivatives or combination therapies offers potential for lifecycle extension. For example, combination with other agents targeting bile acid pathways could address unmet needs in liver diseases, including non-alcoholic steatohepatitis (NASH).
Cost and Manufacturing
Production of ursodiol involves synthesis of complex bile acid derivatives, but manufacturing costs are generally low relative to sales. Entry barriers are minimal post-patent expiration.
Regulatory Landscape
U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals are well-established. New formulations or new indications will require clinical trials and regulatory submissions, potentially taking 3-5 years and costing upwards of $50 million.
Financial Outlook
| Year |
Estimated Revenue |
Revenue Change |
Comments |
| 2023 |
$600 million |
Baseline |
Post-patent expiration preparations |
| 2024 |
$400 million |
-33% |
Increased generic competition |
| 2025 |
$200 million |
-50% |
Significant erosion expected |
Potential for licensing deals or acquisitions before patent expiry exists, especially from smaller biotech firms seeking to extend market exclusivity.
Key Investment Risks
- Patent cliff leading to revenue loss.
- Regulatory hurdles in obtaining approval for new indications.
- Pricing pressures from generic entrants.
- Competition from newer agents like obeticholic acid.
Strategic Recommendations
- Invest in clinical programs exploring additional indications.
- Secure patent extensions via formulation patents or combination therapies.
- Consider licensing deals with generic manufacturers to secure royalty streams.
- Monitor regulatory pathways for potential label expansions.
Key Takeaways
- Ursodiol presents a predictable revenue stream across its current lifecycle, but faces patent expiration within the next two years.
- Market growth is driven by increased disease prevalence and aging demographics.
- Developing new formulations or indications can extend lifecycle and protect margins.
- Competitive landscape narrows with patent expiry; generic competition will pressure prices.
- Investment is most favorable with early positioning before patent expiry, especially via partnerships.
FAQs
1. What are the main therapeutic indications for ursodiol?
Gallstone dissolution and primary biliary cirrhosis.
2. When does patent expiry for ursodiol occur?
Major patents are set to expire in 2024-2025.
3. What is the projected market revenue post-patent expiry?
Revenue could decline to about $200 million by 2025 due to generic entry.
4. Are there ongoing efforts to expand ursodiol’s use?
Yes. Research explores new liver disease indications, including NASH and intrahepatic cholestasis.
5. What are the main competitive threats?
Generic competition, newer therapies like obeticholic acid, and potential pipeline entrants.
References
[1] Sjövall, H., et al. (2017). Gallstone disease prevalence and risk factors. Gastroenterology Review, 15(2), 89–94.
[2] Lau, J. Y., et al. (2018). Primary biliary cirrhosis: Epidemiology and clinical features. Liver International, 38(3), 385–391.
[3] Management of Gallstone and Biliary Diseases. (2022). Global Market Report. Pharma Intelligence.
